Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Fate Therapeutics

DB:F6T
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
F6T
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
  • Fate Therapeutics has significant price volatility in the past 3 months.
F6T Share Price and Events
7 Day Returns
1.9%
DB:F6T
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
33.4%
DB:F6T
-13.2%
DE Biotechs
-20.9%
DE Market
F6T Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Fate Therapeutics (F6T) 1.9% -19.5% 25.9% 33.4% 459.9% 352%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • F6T outperformed the Biotechs industry which returned -13.2% over the past year.
  • F6T outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
F6T
Industry
5yr Volatility vs Market

F6T Value

 Is Fate Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Fate Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €21.4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Fate Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Fate Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:F6T PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.44
NasdaqGM:FATE Share Price ** NasdaqGM (2020-04-03) in USD $22.94
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Fate Therapeutics.

DB:F6T PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:FATE Share Price ÷ EPS (both in USD)

= 22.94 ÷ -1.44

-15.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fate Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Fate Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Fate Therapeutics's expected growth come at a high price?
Raw Data
DB:F6T PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -15.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts
7.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Fate Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Fate Therapeutics's assets?
Raw Data
DB:F6T PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.23
NasdaqGM:FATE Share Price * NasdaqGM (2020-04-03) in USD $22.94
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:F6T PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:FATE Share Price ÷ Book Value per Share (both in USD)

= 22.94 ÷ 3.23

7.1x

* Primary Listing of Fate Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fate Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Fate Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Fate Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

F6T Future Performance

 How is Fate Therapeutics expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Fate Therapeutics expected to grow at an attractive rate?
  • Unable to compare Fate Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Fate Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Fate Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:F6T Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:F6T Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts 7.2%
DB:F6T Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 13 Analysts 59.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:F6T Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:F6T Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 351 123 -14 7
2023-12-31 85 -55 -120 8
2022-12-31 24 -114 -145 8
2021-12-31 7 -115 -146 13
2020-12-31 8 -78 -117 12
2020-04-05
DB:F6T Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 11 -83 -98
2019-09-30 10 -69 -86
2019-06-30 8 -52 -76
2019-03-31 6 -44 -72
2018-12-31 5 -39 -67
2018-09-30 4 -38 -63
2018-06-30 4 -45 -57
2018-03-31 4 -42 -47
2017-12-31 4 -37 -43
2017-09-30 4 -34 -38
2017-06-30 4 -31 -36
2017-03-31 4 -30 -35

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Fate Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Fate Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:F6T Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below

All data from Fate Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:F6T Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.48 3.82 -1.99 7.00
2023-12-31 -1.33 -0.88 -1.94 8.00
2022-12-31 -1.72 -1.37 -2.39 8.00
2021-12-31 -1.80 -1.48 -2.23 12.00
2020-12-31 -1.54 -0.96 -1.81 13.00
2020-04-05
DB:F6T Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.44
2019-09-30 -1.31
2019-06-30 -1.22
2019-03-31 -1.22
2018-12-31 -1.19
2018-09-30 -1.24
2018-06-30 -1.19
2018-03-31 -1.05
2017-12-31 -1.02
2017-09-30 -0.95
2017-06-30 -0.96
2017-03-31 -1.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Fate Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Fate Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Fate Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

F6T Past Performance

  How has Fate Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Fate Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Fate Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Fate Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Fate Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Fate Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Fate Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:F6T Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 10.68 -98.15 23.64
2019-09-30 9.54 -85.87 21.27
2019-06-30 8.14 -76.05 19.01
2019-03-31 6.35 -72.22 17.55
2018-12-31 4.74 -66.60 15.81
2018-09-30 4.11 -63.07 14.89
2018-06-30 4.11 -56.97 13.59
2018-03-31 4.11 -46.96 12.45
2017-12-31 4.11 -42.95 11.87
2017-09-30 4.11 -38.40 10.94
2017-06-30 4.11 -36.45 10.76
2017-03-31 4.11 -35.21 10.34
2016-12-31 4.40 -33.46 9.91
2016-09-30 4.45 -32.97 10.02
2016-06-30 4.45 -31.12 9.76
2016-03-31 3.75 -30.49 10.20
2015-12-31 2.43 -29.99 10.35
2015-09-30 1.36 -28.78 9.88
2015-06-30 0.33 -28.50 9.43
2015-03-31 -26.78 8.81
2014-12-31 -25.88 8.47
2014-09-30 0.00 -25.39 8.26
2014-06-30 0.21 -24.86 8.34
2014-03-31 0.50 -24.33 7.76
2013-12-31 0.97 -20.89 6.64
2013-09-30 1.61 -19.31 6.05
2013-06-30 1.93 -17.35 4.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Fate Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Fate Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Fate Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Fate Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Fate Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

F6T Health

 How is Fate Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Fate Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Fate Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Fate Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Fate Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Fate Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Fate Therapeutics Company Filings, last reported 3 months ago.

DB:F6T Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 244.76 0.00 221.43
2019-09-30 268.04 13.93 302.82
2019-06-30 127.53 14.92 162.01
2019-03-31 145.84 14.90 183.03
2018-12-31 160.47 14.88 201.01
2018-09-30 173.93 14.87 211.19
2018-06-30 51.83 14.85 78.02
2018-03-31 65.00 14.83 88.63
2017-12-31 77.19 14.81 100.95
2017-09-30 45.75 14.79 69.21
2017-06-30 55.21 6.68 71.01
2017-03-31 63.86 8.70 82.30
2016-12-31 73.15 10.69 92.11
2016-09-30 25.37 12.64 46.62
2016-06-30 23.13 14.54 45.93
2016-03-31 30.73 16.41 55.61
2015-12-31 38.04 18.24 64.81
2015-09-30 45.00 19.13 72.86
2015-06-30 51.07 19.70 81.18
2015-03-31 21.25 19.67 42.35
2014-12-31 28.34 19.61 49.10
2014-09-30 33.58 10.00 45.53
2014-06-30 39.64 0.75 42.01
2014-03-31 45.18 1.24 47.88
2013-12-31 50.85 1.73 54.04
2013-09-30 -9.88 25.70 19.08
2013-06-30 -0.15 2.71 3.40
  • Fate Therapeutics has no debt.
  • Fate Therapeutics has no debt compared to 5 years ago when it was 69.4%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Fate Therapeutics has sufficient cash runway for 2.4 years based on current free cash flow.
  • Fate Therapeutics has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 25% each year.
X
Financial health checks
We assess Fate Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Fate Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

F6T Dividends

 What is Fate Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Fate Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Fate Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Fate Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Fate Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:F6T Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:F6T Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Fate Therapeutics has not reported any payouts.
  • Unable to verify if Fate Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Fate Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Fate Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Fate Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Fate Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Fate Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Fate Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

F6T Management

 What is the CEO of Fate Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
J. Wolchko
COMPENSATION $10,720,955
AGE 49
TENURE AS CEO 4.3 years
CEO Bio

Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015. Mr. Wolchko served as Principal Financial Officer and Principal Accounting Officer of Fate Therapeutics, Inc. He serves as the Chief Financial Officer and served as Chief Operations Officer of Fate Therapeutics, Inc. from February 2013 to November 30, 2015. Mr. Wolchko serves as Treasurer and Secretary at Fate Therapeutics, Inc., Mr. Wolchko served as Principal Accounting Officer Treasurer and Secretary at Fate Therapeutics, Inc., and was responsible for financial and business development activities. He served as Vice President of Operations of Fate Therapeutics, Inc. He served as the Chief Financial Officer of Bocada, Inc. Prior to joining Bocada Inc. He has been a Director at Fate Therapeutics, Inc. since October 2015. Mr. Wolchko served as Senior Director of Corporate Development for drugstore.com, where he was responsible for evaluating and executing financial and business development opportunities. Previously, he served in the Investment Banking Division of Morgan Stanley & Co.'s New York City and Menlo Park, California offices for six years. As a member of Morgan Stanley & Co.'s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and strategic transactions. Mr. Wolchko holds an M.S. in Biochemical Engineering from the University of Virginia and a B.S. in Biomedical Engineering from the University of Vermont.

CEO Compensation
  • J.'s compensation has increased whilst company is loss making.
  • J.'s remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Fate Therapeutics management team in years:

2.4
Average Tenure
47.5
Average Age
  • The tenure for the Fate Therapeutics management team is about average.
Management Team

J. Wolchko

TITLE
Founder
COMPENSATION
$11M
AGE
49
TENURE
4.3 yrs

Dan Shoemaker

TITLE
Chief Scientific Officer
COMPENSATION
$3M
AGE
51
TENURE
4.9 yrs

Cindy Tahl

TITLE
General Counsel & Corporate Secretary
COMPENSATION
$3M
AGE
46
TENURE
4.5 yrs

Bob Valamehr

TITLE
Chief Development Officer
COMPENSATION
$3M
AGE
42
TENURE
2.3 yrs

Wen Wang

TITLE
Senior Vice President of Technical Operations
TENURE
1.5 yrs

Jim Beitel

TITLE
Senior Vice President of Corporate Development
TENURE
2.6 yrs

Sarah Cooley

TITLE
Senior Vice President of Clinical Translation
TENURE
1.2 yrs

Wayne Chu

TITLE
Senior Vice President of Clinical Development
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Fate Therapeutics board of directors in years:

9.2
Average Tenure
59
Average Age
  • The tenure for the Fate Therapeutics board of directors is about average.
Board of Directors

Bill Rastetter

TITLE
Chairman
COMPENSATION
$277K
AGE
71
TENURE
8.4 yrs

J. Wolchko

TITLE
Founder
COMPENSATION
$11M
AGE
49
TENURE
4.5 yrs

John Mendlein

TITLE
Vice Chairman of the Board
COMPENSATION
$246K
AGE
59
TENURE
8.4 yrs

Tim Coughlin

TITLE
Independent Director
COMPENSATION
$251K
AGE
52
TENURE
6.7 yrs

Ben Shapiro

TITLE
Member of Scientific Advisory Board
AGE
79

Amir Nashat

TITLE
Independent Director
COMPENSATION
$234K
AGE
46
TENURE
12.6 yrs

Bob Langer

TITLE
Member of Scientific Advisory Board
AGE
70

Stuart Orkin

TITLE
Member of Scientific Advisory Board
TENURE
9.9 yrs

Sean Morrison

TITLE
Member of Scientific Advisory Board
TENURE
9.9 yrs

Mark Krasnow

TITLE
Member of Scientific Advisory Board
TENURE
9.9 yrs
Who owns this company?
Recent Insider Trading
  • Fate Therapeutics individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
10. Jan 20 Sell Daniel Shoemaker Individual 08. Jan 20 08. Jan 20 -5,700 €18.63 €-106,176
10. Jan 20 Sell Bahram Valamehr Individual 08. Jan 20 08. Jan 20 -5,700 €18.62 €-106,141
10. Jan 20 Sell Cindy Tahl Individual 08. Jan 20 08. Jan 20 -5,700 €18.64 €-106,265
16. Oct 19 Sell J. Wolchko Individual 15. Oct 19 15. Oct 19 -21,017 €13.08 €-274,963
16. Oct 19 Sell Bahram Valamehr Individual 15. Oct 19 15. Oct 19 -6,200 €12.84 €-79,638
16. Oct 19 Sell Cindy Tahl Individual 15. Oct 19 15. Oct 19 -10,200 €12.91 €-131,649
16. Oct 19 Sell Daniel Shoemaker Individual 15. Oct 19 15. Oct 19 -11,800 €12.95 €-152,762
17. Sep 19 Buy Redmile Group, LLC Company 16. Sep 19 16. Sep 19 857,143 €15.91 €13,639,502
X
Management checks
We assess Fate Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Fate Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

F6T News

Simply Wall St News

F6T Company Info

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company’s immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Details
Name: Fate Therapeutics, Inc.
F6T
Exchange: DB
Founded: 2007
$1,614,663,147
75,937,385
Website: http://www.fatetherapeutics.com
Address: Fate Therapeutics, Inc.
3535 General Atomics Court,
Suite 200,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM FATE Common Stock Nasdaq Global Market US USD 01. Oct 2013
DB F6T Common Stock Deutsche Boerse AG DE EUR 01. Oct 2013
Number of employees
Current staff
Staff numbers
178
Fate Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 23:07
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.